TrialArthritis & rheumatology (Hoboken, N.J.)2017

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Nicola Dalbeth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.